Severe cutaneous adverse drug reactions: Who should treat, Where and how?: Facts and controversies

Ronni Wolf*, Batya Davidovici

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are uncommon but extremely serious and often life-threatening mucocutaneous reactions characterized by extensive epithelial sloughing and systemic symptoms. There is no effective evidence-based treatment for severe cutaneous adverse reactions (SCAR) to drugs and no consensus on how to treat these patients. This contribution presents some of the controversies concerning the treatment of SCAR patients, including where and by whom, as well as the issue of the value of treatment with corticosteroids and intravenous immunoglobulin. Investigators agree that more studies are needed and that there are insufficient data to draw definite conclusions. The spectrum of disagreement is wide and the debate is ongoing. At the end, the important question is should we wait with our decisions until all these controversies are settled and we have more or full evidence. This question, as well as all others, is open for debate, evidently a "toxic" debate on toxic epidermal necrolysis.

Original languageEnglish
Pages (from-to)344-348
Number of pages5
JournalClinics in Dermatology
Volume28
Issue number3
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Dive into the research topics of 'Severe cutaneous adverse drug reactions: Who should treat, Where and how?: Facts and controversies'. Together they form a unique fingerprint.

Cite this